3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Leukemia
7
Leukemia, Myeloid, Acute
6
Medulloblastoma
5
Lymphoma
5
Sarcoma
4
Hematologic Neoplasms
4
Central Nervous System Neoplasms
4
Brain Neoplasms
4
Astrocytoma
4
Rhabdoid Tumor
3
Ovarian Neoplasms
3
Glioma
3
Ependymoma
3
Burkitt Lymphoma
3
Anemia, Refractory, with Excess of Blasts
3
Wilms Tumor
2
Rhabdomyosarcoma
2
Retinoblastoma
2
Primary Myelofibrosis
2
Pinealoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large-Cell, Immunoblastic
2
Liver Neoplasms
2
Leukemia, Myelomonocytic, Chronic
2
Interventions
Brentuximab Vedotin
7
dacetuzumab
4
Lenalidomide
3
Doxorubicin
3
Dexamethasone
3
spartalizumab
2
lintuzumab
2
fludarabine
2
Vincristine
2
Rituximab
2
Rifampin
2
Prednisone
2
Gemcitabine
2
Cyclophosphamide
2
tanespimycin
1
sabatolimab
1
pomalidomide
1
pirtobrutinib
1
fludarabine phosphate
1
ficlatuzumab
1
daratumumab
1
Vinblastine
1
Thiotepa
1
TAS4464
1
Sertraline
1
R-CHOP protocol
1
Pam2CSK4 acetate and ODN M362 combination
1
Midazolam
1
Melphalan
1
LCL161
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Hematologic Diseases
×
Thiotepa
×
Clear all
NCT02660281
2021-11-03
HaploOnly
University of Rochester
Phase 1
Completed
74 enrolled